![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1561483
¼¼°èÀÇ ³»½Ã°æ Àçó¸® ½ÃÀå º¸°í¼ : Á¦Ç°, °øÁ¤, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°(2024-2032³â)Endoscope Reprocessing Market Report by Product, Process, End User, and Region 2024-2032 |
¼¼°è ³»½Ã°æ Àçó¸® ½ÃÀå ±Ô¸ð´Â 2023³â 22¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 40¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2024³âºÎÅÍ 2032³â±îÁö 6.8%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ÁÖ·Î ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í °¨¿° °ü¸®¿Í °ü·ÃµÈ ¾ö°ÝÇÑ ±ÔÁ¦ ½ÃÇà¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àçó¸® ÀåºñÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü, ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ³»½Ã°æ ¼ö¼úÀÇ ±Þ°ÝÇÑ Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ³»½Ã°æ Àçó¸® ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä µ¿ÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ³»½Ã°æÀ» ÀÌ¿ëÇÑ ¼ö¼úÀº ±âÁ¸ ¼ö¼ú¿¡ ºñÇØ ȸº¹ ½Ã°£ ´ÜÃà, °¨¿° À§Çè °¨¼Ò, ¼ö¼ú ÈÄ ÅëÁõ °¨¼Ò µîÀÇ ÀåÁ¡ÀÌ ÀÖÀ¸¸ç, National Center for Biotechnology¿¡ ¹ßÇ¥µÈ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â ¿¬°£ ¾à 1,700¸¸ °ÇÀÇ ¼ÒȰü(GI) ³»½Ã°æ ¼ö¼úÀÌ ½ÃÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Àüü ³»½Ã°æ ¼ö¼úÀÇ 68%¸¦ Â÷ÁöÇÕ´Ï´Ù. ³»½Ã°æ ¼ö¼úÀº Àüü ³»½Ã°æ ¼ö¼úÀÇ 68%¸¦ Â÷ÁöÇϸç, GI ³»½Ã°æ ½Ã¼ú ÈÄ º¹ÇÕ °¨¿°·üÀº 0.2%À̸ç, ƯÁ¤ ½Ã¼úÀÇ °æ¿ì ERCP´Â 0.8%, ERCP¸¦ Á¦¿ÜÇÑ »óºÎÀ§Àå°ü ³»½Ã°æ 0.123%, ÇϺÎÀ§Àå°ü ³»½Ã°æ 0.073%·Î ´õ ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ³»½Ã°æ ½Ã¼ú ºóµµ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ³»½Ã°æÀÇ ¾ÈÀü°ú ¼ö¸íÀ» º¸ÀåÇϱâ À§ÇÑ È¿°úÀûÀÎ Àçó¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
°·ÂÇÑ °¨¿° °ü¸® ±ÔÁ¤ ½ÃÇà
¾÷°è º¸°í¿¡ µû¸£¸é ¿¬¼º ³»½Ã°æ Àçó¸® ½ÇÆÐ´Â º´¿ø ³» °¨¿°(HAI)°ú °ü·ÃÀÌ ÀÖ¾î ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ¿¡ Å« ºÎ´ãÀ» ÁÖ°í ÀÖÀ¸¸ç, HAI´Â ȯÀÚ¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ºÎÀÛ¿ëÀ¸·Î °¡Àå ¸¹ÀÌ º¸°íµÈ ºÎÀÛ¿ëÀ¸·Î À¯·´ Àüü¿¡¼ 6.5%ÀÇ À¯º´·üÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¼ö¼ú ºÎÀ§ °¨¿°Àº Àüü HAIÀÇ 18.3%¸¦ Â÷ÁöÇϸç ȯÀÚÀÇ »îÀÇ Áú¿¡ ¾Ç¿µÇâÀ» ¹ÌÄ¡°í ÀÌȯÀ²°ú »ç¸Á·üÀ» Áõ°¡½Ãŵ´Ï´Ù. ¶ÇÇÑ ÀÇ·á ½Ã½ºÅÛ¿¡ ¸·´ëÇÑ °æÁ¦Àû ºÎ´ãÀ» ÁÖ´Â ¿äÀÎÀ̱⵵ ÇÕ´Ï´Ù. µ¶ÀÏ¿¡¼ ¼ö¼ú ºÎÀ§ °¨¿°Àº Æò±Õ 17.9ÀÏÀÇ ÀÔ¿ø ±â°£ ¿¬Àå°ú ȯÀÚ 1Àδç 22,905 À¯·ÎÀÇ Ãß°¡ ÀÇ·áºñ¸¦ ÃÊ·¡ÇÕ´Ï´Ù. ÀÌ¿¡ µû¶ó °¢±¹ Á¤ºÎ¿Í ÀÇ·á ±â°üÀº º´¿ø ³» °¨¿°(HAI)À» ¿¹¹æÇϱâ À§ÇØ ¾ö°ÝÇÑ ±ÔÁ¦¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦¸¦ ÁؼöÇϰí ó¹úÀ» ÇÇÇϱâ À§ÇØ ÀÇ·á ±â°üÀº ÷´Ü ³»½Ã°æ Àçó¸® ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ³»½Ã°æÀ» öÀúÈ÷ ¼¼Ã´, ¼Òµ¶ ¹× ¸ê±ÕÇÏ¿© HAIÀÇ À§ÇèÀ» ÁÙÀ̰í ȯÀÚ ¾ÈÀüÀ» Çâ»ó½Ãŵ´Ï´Ù.
Àçó¸® ÀåºñÀÇ ±â¼úÀû Áøº¸
±â¼úÀÇ ¹ßÀüÀº ³»½Ã°æ Àçó¸® ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿ Àçó¸® Àåºñ, °ÈµÈ ¼Òµ¶Á¦, Á¤±³ÇÑ ÃßÀû ½Ã½ºÅÛ°ú °°Àº ±â¼ú Çõ½ÅÀº Àçó¸® °øÁ¤ÀÇ È¿À²¼º°ú ½Å·Ú¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ³»½Ã°æÀÌ ÀϰüµÇ°Ô ³ôÀº ¼öÁØÀ¸·Î ¼¼Ã´µÇµµ·Ï º¸ÀåÇϰí, ÀÎÀû ¿À·ùÀÇ À§ÇèÀ» ÁÙÀ̸ç, ÀÇ·á ½Ã¼³ÀÇ ¿öÅ©Ç÷ο츦 °£¼ÒÈÇϰí, ³»½Ã°æ Àçó¸® ¼Ö·ç¼ÇÀÇ Ã¤Åðú È®Àå¿¡ Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù, À¯¿¬ÇÑ ·Îº¿ ±â±â °³¹ß ¾÷üÀÎ ¾ÖÁú¸®½º ·Îº¸Æ½½º(Agilis Robotics)´Â ÀÚü °³¹ßÇÑ ³»½Ã°æ ¼ö¼ú¿ë ·Îº¿ÀÇ µÎ ¹øÂ° µ¿¹°½ÇÇèÀ» ¿Ï·áÇß½À´Ï´Ù. ±× °á°ú, ·Îº¿ ½Ã½ºÅÛÀÇ À¯È¿¼º, Á¤È®¼º ¹× ¾ÈÀü¼º Ãø¸é¿¡¼ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ¾ú½À´Ï´Ù. ±× °á°ú, ³»½Ã°æ ¼ö¼ú¿¡ ·Îº¿ °øÇÐÀÇ ÅëÇÕÀÌ ÁøÇàµÊ¿¡ µû¶ó ¼ö¼ú °Ç¼ö°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
IMARC GroupÀº °¢ ½ÃÀå ºÎ¹®ÀÇ ÁÖ¿ä µ¿Ç⠺м®°ú 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è, Áö¿ª ¹× ±¹°¡º° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼´Â Á¦Ç°, ÇÁ·Î¼¼½º ¹× ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±âÁØÀ¸·Î ½ÃÀåÀ» ºÐ·ùÇÕ´Ï´Ù.
³ôÀº ¼öÁØÀÇ ¼Òµ¶Á¦¿Í Å×½ºÆ® ½ºÆ®¸³ÀÌ ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â Á¦Ç°º°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â °í¼öÁØ ¼Òµ¶Á¦ ¹× Å×½ºÆ® ½ºÆ®¸³, ¼¼Á¦ ¹× ¹°Æ¼½´, ÀÚµ¿ ³»½Ã°æ ¸®ÇÁ·Î¼¼¼, ³»½Ã°æ °ÇÁ¶, º¸°ü ¹× ¿î¹Ý ½Ã½ºÅÛ, ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼¿¡ µû¸£¸é, °í¼öÁØ ¼Òµ¶Á¦ ¹× Å×½ºÆ® ½ºÆ®¸³ÀÌ °¡Àå Å« ºÎ¹®ÀÔ´Ï´Ù.
³ôÀº ¼öÁØÀÇ ¼Òµ¶Á¦ ¹× Å×½ºÆ® ½ºÆ®¸³Àº ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇÏ´Â È¿°ú¿Í È¿À²¼ºÀ¸·Î ³»½Ã°æ Àçó¸® ½ÃÀåÀÇ °¡Ä¡¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ ¼Òµ¶Á¦´Â °áÇÙ±Õ°ú Ŭ·Î½ºÆ®¸®µã µðÇǽDZհú °°Àº ³»¼º±ÕÀ» Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ º´¿ø±ÕÀ» Á¦°ÅÇϵµ·Ï Ưº°È÷ °í¾ÈµÈ Á¦Ç°ÀÔ´Ï´Ù. ºü¸¥ È¿°ú¿Í ÀÚµ¿ Àçó¸® Àåºñ¿¡ ÀûÇÕÇϱ⠶§¹®¿¡ ¹Ù»Û ÀÇ·á ÇöÀå¿¡¼ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. Å×½ºÆ® ½ºÆ®¸³Àº ¼Òµ¶ °úÁ¤ÀÇ È¿°ú¸¦ °ËÁõÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¼Òµ¶Á¦ÀÇ ÃÖ¼Ò ±ÇÀå ³óµµ°¡ ÃæÁ·µÇ¾ú´ÂÁö Áï½Ã È®ÀÎÇÒ ¼ö ÀÖ¾î ¾ÈÀü ±âÁØ Áؼö¸¦ º¸ÀåÇÏ°í °¨¿° À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¶óÇÇ½Ãµå °í³óµµ ¼Òµ¶Á¦´Â ±Û·çŸ¸£¾Ëµ¥È÷µå ±â¹Ý, Áï°¢ÀûÀÎ È¿°ú, ÀÚµ¿ ¸®ÇÁ·Î¼¼¼¿¡¼ ¿¬¼º ³»½Ã°æÀ» À§ÇÑ Àç»ç¿ë °¡´ÉÇÑ ¼Ö·ç¼ÇÀ¸·Î È¥ÇÕ ¹× Ȱ¼ºÈ°¡ ÇÊ¿ä ¾ø´Â DSD-201°ú °°Àº ½Ã½ºÅÛÀ¸·Î ¿¿¡ ¹Î°¨ÇÑ ÁØÁß¿ä ÀÇ·á±â±â¸¦ Àçó¸®ÇÏ°í °áÇÙ±Õ, C. diff, CRE¿Í °°Àº º´¿ø±ÕÀ» Á¦°ÅÇÒ ¼ö ÀÖ½À´Ï´Ù. diff, CRE¿Í °°Àº º´¿ø±ÕÀ» 35¡ÆC(95¡ÆF)¿¡¼ 5ºÐÀÇ Á¢ÃË ½Ã°£À¸·Î ºñȰ¼ºÈÇÕ´Ï´Ù. RAPICIDE(TM) Å×½ºÆ® ½ºÆ®¸³Àº 3ÃÊÀÇ Ä§Áö ¹× 75ÃÊÀÇ ÆÇµ¶ ½Ã°£À¸·Î ±Û·çŸ¸£¾Ëµ¥È÷µåÀÇ ÃÖ¼Ò ±ÇÀå ³óµµ¸¦ È®ÀÎÇϸç, ¼Òµ¶¾×Àº µÎ ¹øÀÇ Çó±ÀÀ¸·Î È¿À²¼ºÀ» ³ôÀÔ´Ï´Ù. ÀÌ »ç·Ê´Â ƯÁ¤ Á¦Ç°ÀÌ ½ÃÀå¿¡¼ ³ôÀº ¼öÁØÀÇ ¼Òµ¶Á¦ ¹× Å×½ºÆ® ½ºÆ®¸³¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ¿© ³»½Ã°æ Àçó¸® ½ÃÀåÀÇ °¡Ä¡¸¦ ³ôÀÌ´Â ¹æ¹ýÀ» º¸¿©ÁÝ´Ï´Ù.
ÀÚµ¿ ¼¼Ã´ÀÌ ¾÷°è Á¡À¯À² 1À§
ÀÌ º¸°í¼´Â °øÁ¤º°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¼öµ¿ ¼¼Ã´°ú ÀÚµ¿ ¼¼Ã´ÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼¿¡ µû¸£¸é ÀÚµ¿ ¼¼Ã´ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
ÀÚµ¿ ¼¼Ã´ÀÌ ³»½Ã°æ Àçó¸® ½ÃÀåÀ» Àå¾ÇÇϰí ÀÖ´Â ÀÌÀ¯´Â ÀϰüµÇ°í ³ôÀº ¼öÁØÀÇ ¼Òµ¶À» º¸ÀåÇÏ°í ¼öµ¿ ¼¼Ã´À¸·Î ÀÎÇÑ ÀÎÀû ¿À·ùÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÚµ¿ ³»½Ã°æ Àç󸮱â(AER)¿Í °°Àº ÀÚµ¿È ½Ã½ºÅÛÀº Ç¥ÁØÈµÇ°í È¿À²ÀûÀ̸ç È¿°úÀûÀÎ ¼¼Ã´ ¹× ¼Òµ¶ ÇÁ·Î¼¼½º¸¦ Á¦°øÇÏ¿© ȯÀÚ ¾ÈÀü¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ³»½Ã°æ Àç󸮿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ³ëµ¿·ÂÀ» ÃÖ¼ÒÈÇÏ¿© ÀÇ·á ½Ã¼³ÀÇ ¿öÅ©Ç÷οì È¿À²¼ºÀ» ³ôÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿ ¼¼Ã´ ½Ã½ºÅÛÀº Ãֽг»½Ã°æÀÇ º¹ÀâÇÑ µðÀÚÀο¡ ¸Â°Ô Ưº°È÷ ¼³°èµÇ¾î öÀúÇÑ ¿À¿° Á¦°Å¿Í ¾ö°ÝÇÑ ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ³»½Ã°æ Àçó¸® ½ÃÀå ¿¹Ãø¿¡ µû¸£¸é, ±â¼ú ¹ßÀü°ú ½Å·ÚÇÒ ¼ö ÀÖ°í È¿À²ÀûÀÎ Àçó¸® ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÀÚµ¿ ¼¼Ã´ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹¸¦ µé¾î, 2023³â 3¿ù HOYA ±×·ìÀÇ ÇÑ ºÎ¹®ÀÎ PENTAX MedicalÀº PlasmaBiotics¿Í °øµ¿À¸·Î °³¹ßÇÑ Çõ½ÅÀûÀÎ ÀÚµ¿ Àüó¸® ¼Ö·ç¼ÇÀÎ AquaTYPHOONÀ¸·Î CE ¸¶Å©¸¦ ȹµæÇß½À´Ï´Ù. ±âÁ¸ ¼öÀÛ¾÷À¸·Î ÀÌ·ïÁö´ø ³»½Ã°æ Àçó¸® °úÁ¤À» ´ëüÇÒ ¼ö ÀÖ´Â °·ÂÇÑ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ÀÇ·áÁøÀÌ ÀÏ»ó ÀÓ»ó¿¡¼ Á÷¸éÇÏ´Â À§»ý ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÒ ¼ö ÀÖ½À´Ï´Ù.
º´¿ø ¹× Áø·á¼Ò°¡ ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®À» Â÷ÁöÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ÃÖÁ¾ »ç¿ëÀÚº°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼¿¡ µû¸£¸é, º´¿ø ¹× Ŭ¸®´ÐÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼¼ºÐÈ Á¶»ç º¸°í¼´Â º´¿ø ¹× Ŭ¸®´ÐÀÌ ½ÃÀåÀÇ Áö¹èÀû ÀÎ ºÎ¹®ÀÓÀ» °Á¶ÇÕ´Ï´Ù. ¾÷°è º¸°í¼¿¡ µû¸£¸é ¾ÆÀÏ·£µåÀÇ ºñ¸¸ ¼ö¼ú °Ç¼ö´Â 2023³â 219 °Ç¿¡ ´ÞÇϰí, º¸°Ç ¼ºñ½º °ü¸®±¹(HSE)ÀÌ ¼³Á¤ ÇÑ ¼öÁ¤ ¸ñÇ¥ ÀÎ 200 °ÇÀ» Å©°Ô »óȸÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â 2022³â 109°Ç¿¡¼ Å©°Ô Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ ¼ö¼úÀº ´õºí¸°ÀÇ ¼¼ÀÎÆ® ºó¼¾Æ® ´ëÇк´¿ø, ´ø¶ó¿ÀÇì¾îÀÇ ¼¼ÀÎÆ® ¸¶ÀÌŬ½º º´¿ø, °ñ¿þÀÌ ´ëÇк´¿ø µî ¼¼ °÷ÀÇ HSE ½Ã¼³¿¡¼ ÀÌ·ç¾îÁ³½À´Ï´Ù. ¶ÇÇÑ °ñ¿þÀÌ ´ëÇк´¿ø¿¡¼¸¸ 2023³â¿¡ 49°ÇÀÇ ¼ö¼úÀÌ ½ÃÇàµÇ¾î Àü³âµµ 19°Ç¿¡¼ Áõ°¡ÇÏ¿´½À´Ï´Ù.
ÀÌ·¯ÇÑ ½Ã¼³¿¡¼´Â º´¿ø ³» °¨¿°À» ¿¹¹æÇϱâ À§ÇØ ¾ö°ÝÇÑ °¨¿° ´ëÃ¥ÀÌ ÇÊ¿äÇϸç, È¿°úÀûÀÎ Àç󸮰¡ ÇʼöÀûÀÔ´Ï´Ù. ³»½Ã°æÀ» ÀÚÁÖ »ç¿ëÇÏ´Â ÃÖ¼Òħ½À ¼ö¼úÀÇ º¸±ÞÀº ÀÌ·¯ÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ¿ä°Ç°ú °¡À̵å¶óÀÎÀº ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ Àçó¸® ÇÁ·ÎÅäÄÝÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ½Ã¼ú °Ç¼ö, ±ÔÁ¦ Áؼö ¹× °¨¿° ¿¹¹æ¿¡ ´ëÇÑ Áß¿äÇÑ ¿ä±¸°¡ °áÇÕµÇ¾î º´¿ø ¹× Ŭ¸®´ÐÀº ³»½Ã°æ Àçó¸® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ºÎ¹®À¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.
ºÏ¹Ì°¡ ½ÃÀåÀ» ¼±µµÇÏ°í ³»½Ã°æ Àçó¸® ½ÃÀå Á¡À¯À²ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ·¯½Ã¾Æ, ±âŸ), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ, Àεµ³×½Ã¾Æ, ±âŸ), ¶óƾ¾Æ¸Þ¸®Ä«(ºê¶óÁú, ¸ß½ÃÄÚ, ±âŸ), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µî ÁÖ¿ä Áö¿ª ½ÃÀåÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù. ÁÖ¿ä Áö¿ª ½ÃÀåµµ Á¾ÇÕÀûÀ¸·Î ºÐ¼®Çß½À´Ï´Ù. º¸°í¼¿¡ µû¸£¸é ºÏ¹Ì´Â ³»½Ã°æ Àçó¸®ÀÇ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀÔ´Ï´Ù.
³»½Ã°æ Àçó¸® ½ÃÀå¿¡¼ ºÏ¹ÌÀÇ ¿ìÀ§´Â ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ, ³»½Ã°æ ½Ã¼ú ºóµµ°¡ ³ô±â ¶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ¸¶Ãë°ú ÇÐȸ(American Society of Anesthesiologists)ÀÇ 2024³â ±â»ç¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â ¿¬°£ ¾à 610¸¸ °ÇÀÇ »óºÎ ³»½Ã°æ °Ë»ç°¡ ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CDC º¸°í¼¿¡ µû¸£¸é ¾à 1¾ï 2,900¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ Àû¾îµµ ÇÑ °¡Áö ÀÌ»óÀÇ ÁÖ¿ä ¸¸¼º ÁúȯÀ» ¾Î°í ÀÖ¾î ³»½Ã°æ Àçó¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áø´Ü°ú Ä¡·á ¸ñÀûÀ¸·Î ³»½Ã°æ ½Ã¼úÀÌ º¸Æíȵʿ¡ µû¶ó ³»½Ã°æ Àçó¸® ½ÃÀå Àü¸ÁÀº È¿°úÀûÀÎ Àçó¸® ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀÇ·á ½Ã½ºÅÛÀº °¨¿°À» ¿¹¹æÇϱâ À§ÇØ ³»½Ã°æ Àç󸮸¦ È¿°úÀûÀ¸·Î º¸ÀåÇÏ´Â Á¤±³ÇÑ ±â¼ú°ú ÇÁ·ÎÅäÄÝÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áÁø°ú ȯÀÚÀÇ °¨¿° °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü°ú ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ºÏ¹Ì ½ÃÀå¿¡¼ÀÇ ¼±µµÀû ÁöÀ§¸¦ ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.
(ÀÌ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀ̸ç, Àüü ¸ñ·ÏÀº º¸°í¼¿¡ ³ª¿Í ÀÖ½À´Ï´Ù)
The global endoscope reprocessing market size reached US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032. The market is primarily being driven by the rising demand for minimally invasive surgeries, and the implementation of stringent regulations on infection control. Additionally, rapid technological advancements in reprocessing equipment, growing awareness about patient safety, and the surging prevalence of endoscopy procedures are further contributing to the market growth.
Increasing Demand for Minimally Invasive Surgeries
The rising preference for minimally invasive surgeries is acting as a major driver for the endoscope reprocessing market growth. These procedures, which use endoscopes, offer benefits such as reduced recovery time, lower risk of infection, and less postoperative pain compared to traditional surgeries. According to the data published on National Center for Biotechnology, approximately 17.7 million gastrointestinal (GI) endoscopic procedures are performed annually in the United States, accounting for 68% of all endoscopic procedures. The composite infection rate following GI endoscopic procedures was 0.2%, with higher rates for specific procedures: 0.8% for ERCP, 0.123% for non-ERCP upper GI endoscopies, and 0.073% for lower GI endoscopies. As a result, the frequency of endoscopic procedures is increasing, leading to a higher demand for effective reprocessing solutions to ensure the safety and longevity of endoscopes.
Implementation of Stringent Infection Control Regulations
As per industry reports, failures in reprocessing flexible endoscopes are associated with hospital-acquired infections (HAIs), which place a significant burden on patients and healthcare systems. HAIs are the most reported adverse events affecting patients, with a prevalence of 6.5% across Europe. Surgical site infections, comprising 18.3% of all HAIs, negatively affect patient quality of life and increase morbidity and mortality rates. They also contribute to a significant financial burden on healthcare systems. In Germany, surgical site infections can lead to an average hospital stay extension of 17.9 days and an additional healthcare cost of €22,905 per patient. As a result, governments and healthcare organizations worldwide are implementing stringent regulations to prevent hospital-acquired infections (HAIs). To comply with these regulations and avoid penalties, healthcare facilities are investing in advanced endoscope reprocessing systems. This ensures that endoscopes are thoroughly cleaned, disinfected, and sterilized, thereby reducing the risk of HAIs and improving patient safety.
Technological Advancements in Reprocessing Equipment
Advancements in technologies are significantly driving the endoscope reprocessing market growth. Innovations, such as automated reprocessing machines, enhanced disinfectants, and sophisticated tracking systems, have improved the efficiency and reliability of the reprocessing process. These technologies ensure that endoscopes are consistently cleaned to high standards, reduce the risk of human error, and streamline the workflow in healthcare facilities, making them a critical factor in the adoption and expansion of endoscope reprocessing solutions. For instance, in January 2023, Agilis Robotics, a leading developer of flexible robotic instruments, completed its second round of live animal testing with its proprietary robot for endoscopic surgery. The results demonstrated promising outcomes in terms of efficacy, accuracy, and safety of the robotic system. Consequently, the increasing integration of robotics in endoscopic surgery is expected to boost the number of procedures performed, thereby driving market growth.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, process, and end user.
High-level disinfectants and test strips account for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the product. This includes high-level disinfectants and test strips, detergents and wipes, automated endoscope reprocessors, endoscope drying, storage and transport systems, and others. According to the report, high-level disinfectants and test strips represented the largest segment.
High-level disinfectants and test strips are enhancing the endoscope reprocessing market value due to their effectiveness and efficiency in ensuring patient safety. These disinfectants are specifically designed to eliminate a broad spectrum of pathogens, including highly resistant organisms such as Mycobacterium tuberculosis and Clostridium difficile. Their fast-acting nature and compatibility with automated reprocessors make them a preferred choice in busy healthcare settings. Test strips play a crucial role in validating the efficacy of the disinfection process, providing immediate confirmation that the minimum recommended concentration of the disinfectant is met, thus ensuring compliance with safety standards and reducing the risk of infections. For instance, RAPICIDE high-level disinfectant is a glutaraldehyde-based, fast-acting, reusable solution for flexible endoscopes in automated reprocessors, requiring no mixing or activation. It reprocesses heat-sensitive, semi-critical medical devices in systems like the DSD-201, inactivating pathogens such as TB, C-diff, and CRE with a 5-minute contact time at 95°F (35°C). The disinfectant enhances efficiency with only two rinses needed. RAPICIDE(TM) Test Strips confirm the minimum recommended concentration of glutaraldehyde, requiring a 3-second dip and a 75-second read time. This example illustrates how specific products drive the demand for high-level disinfectants and test strips in the market, thereby increasing the endoscope reprocessing market value.
Automated cleaning holds the largest share of the industry
A detailed breakup and analysis of the market based on the process have also been provided in the report. This includes manual cleaning and automated cleaning. According to the report, automated cleaning accounted for the largest market share.
Automated cleaning dominates the endoscope reprocessing market due to its ability to ensure consistent and high-level disinfection, reducing the risk of human error associated with manual cleaning. Automated systems, such as automated endoscope reprocessors (AERs), provide standardized, efficient, and effective cleaning and disinfecting processes, which are critical for patient safety. These systems enhance workflow efficiency within healthcare facilities by minimizing both the time and labor involved in reprocessing endoscopes. Additionally, automated cleaning systems are specifically designed to accommodate the intricate designs of modern endoscopes, ensuring thorough decontamination and adherence to stringent regulatory standards. As part of the endoscope reprocessing market forecast, it is expected that the growing adoption of automated cleaning solutions will continue to shape the market, driven by advancements in technology and the increasing demand for reliable and efficient reprocessing methods.
For instance, in March 2023, PENTAX Medical, a division of the HOYA Group, was awarded the CE mark for its innovative automated pre-cleaning solution, the AquaTYPHOON. Developed in collaboration with PlasmaBiotics, this device offers a robust alternative to the traditional manual pre-cleaning step in endoscope reprocessing, effectively addressing the hygiene challenges healthcare providers encounter in daily clinical practice.
Hospitals and clinics represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, ambulatory surgery centers, and others. According to the report, hospitals and clinics represented the largest segment.
The endoscope reprocessing market research report highlights that hospitals and clinics are the dominant segment in the market, attributed to the large volume of endoscopic procedures conducted within these facilities. According to industry reports, the number of bariatric surgery procedures in Ireland reached 219 in 2023, significantly surpassing the revised target of 200 set by the Health Service Executive (HSE). This marked a substantial increase from the 109 procedures performed in 2022. These surgeries were conducted at three HSE sites: St Vincent's University Hospital in Dublin, St Michael's Hospital in Dun Laoghaire, and University Hospital Galway. Additionally, University Hospital Galway alone performed 49 surgeries in 2023, up from 19 in the previous year.
These facilities require stringent infection control measures to prevent hospital-acquired infections, making effective reprocessing essential. The increasing prevalence of minimally invasive surgeries, which frequently utilize endoscopes, further drives demand. Additionally, regulatory requirements and guidelines mandate rigorous reprocessing protocols to ensure patient safety. The combination of high procedural volume, regulatory compliance, and the critical need for infection prevention establishes hospitals and clinics as the primary market segment for endoscope reprocessing.
North America leads the market, accounting for the largest endoscope reprocessing market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for endoscope reprocessing.
North America's dominance in the endoscope reprocessing market can be attributed to its advanced healthcare infrastructure, increasing prevalence of chronic diseases, stringent regulatory standards, and high frequency of endoscopic procedures. For example, a 2024 article by the American Society of Anesthesiologists indicates that approximately 6.1 million upper endoscopies are performed annually in the U.S. Furthermore, the CDC reports that around 129 million Americans suffer from at least one major chronic condition, significantly driving the need for endoscope reprocessing solutions. As endoscopic procedures become more common for both diagnostic and therapeutic purposes, the endoscope reprocessing market outlook reflects a growing demand for effective reprocessing technologies. The region's healthcare systems, equipped with sophisticated technologies and protocols, ensure effective endoscope reprocessing to prevent infections. Additionally, heightened awareness of infection control among healthcare providers and patients, along with continuous technological advancements and a focus on patient safety, further solidify North America's leading position in the market.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)